Tenaya Therapeutics (TNYA) EBT (2020 - 2026)

Tenaya Therapeutics has reported EBT for 7 years, with the latest figure at -$19.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 28.26% year-over-year to -$19.3 million; the trailing twelve-month figure through Mar 2026 stood at -$83.0 million (up 21.52% YoY), and the FY2025 full-year result was -$90.6 million, up 18.48% from the prior year.
• EBT for Q1 2026 stood at -$19.3 million, up from -$20.2 million in the prior quarter.
• The five-year high for EBT was -$19.3 million in Q1 2026, with the low at -$33.5 million in Q4 2022.
• Average EBT over 5 years is -$27.6 million, with a median of -$29.1 million recorded in 2023.
• Year-over-year, EBT tumbled 137.1% in 2022 and climbed 28.26% in 2026.
• Tracing TNYA's EBT over 5 years: stood at -$33.5 million in 2022, then advanced by 10.68% to -$29.9 million in 2023, then increased by 20.37% to -$23.8 million in 2024, then grew by 15.36% to -$20.2 million in 2025, then increased by 4.48% to -$19.3 million in 2026.
• The last three EBT figures came in at -$19.3 million (Q1 2026), -$20.2 million (Q4 2025), and -$20.3 million (Q3 2025), per Business Quant data.

Peer Comparison